GLP-1s and Exercise: A Better-Together Story

GLP-1 medications like semaglutide drive weight loss reliably enough that it is tempting to treat exercise as optional. The more interesting question is not whether training adds a few extra pounds of loss — it is whether training changes what kind of weight you lose. On that question, the evidence points somewhere genuinely useful.

The composition problem

Any large, rapid weight loss — from dieting, surgery, or these drugs — tends to come partly from lean mass, not just fat. The STEP 1 body-composition substudy (published in the Journal of the Endocrine Society in 2021, n=140) put numbers on it: over 68 weeks, participants on semaglutide lost about 15% of body weight, with total fat mass down ~19% and lean body mass down ~9.7%.

Importantly, that does not mean the loss was bad-quality. Because fat fell faster than lean tissue, lean mass as a proportion of body weight actually rose by about 3 percentage points, and the lean-to-fat ratio improved. The concern isn’t that GLP-1s preferentially strip muscle — it’s that meaningful absolute lean-mass loss still happens, and that matters for strength and long-term function, especially in older adults.

This is where exercise stops being a footnote. Beetroot, beets, vegetables — illustrating GLP-1s and Exercise: A Better-Together Story

The honest framing: GLP-1s reduce the total number on the scale and, on average, improve body composition. But absolute lean mass still falls. Resistance training is the most direct lever we have to protect muscle during the deficit.

What training appears to contribute

Resistance work provides the mechanical signal that tells the body to preserve lean tissue in a calorie deficit. The European Association for the Study of Obesity’s physical-activity group highlights resistance training — over aerobic exercise — as the modality that best attenuates lean-mass loss during weight loss.
Adequate protein pairs with that signal; without it, the stimulus has less to work with.
Aerobic work supports cardiovascular fitness and may help with mood and adherence over a long course.

It’s worth being honest about a gap: large randomized trials specifically pairing structured resistance training with GLP-1 therapy are still in progress (for example, the LEAN-PREP study testing resistance exercise and protein during semaglutide/tirzepatide treatment). So the muscle-preservation case rests on body-composition data plus well-established exercise physiology, not yet on definitive combination-trial outcomes. Treat the specifics as well-grounded but still maturing.

Why the combination may compound

Carrots, vegetables, harvest — illustrating GLP-1s and Exercise: A Better-Together Story

There’s a plausible mechanistic story beyond simple addition. Reduced appetite makes a calorie deficit easier to sustain, which makes consistent training easier to adhere to. Better-preserved muscle keeps resting energy expenditure higher, supporting the deficit. None of this is guaranteed — it’s a reinforcing loop that works when both halves are present and tends to unravel when either is missing.

The maintenance angle

Weight regain after stopping these drugs is common — the STEP 1 extension showed substantial regain after withdrawal. The reasonable expectation is that people who built an exercise habit and protected their muscle during treatment are better positioned for what comes next, because the habit and the metabolic capacity outlast the prescription.

The takeaway

Exercise will not double your GLP-1 results, and we shouldn’t pretend it does. What it appears to do is more valuable: protect the lean mass the drug still costs you in absolute terms, and leave you with capacity that persists when the medication stops. If you’re on one of these drugs, resistance training and adequate protein are not the part to skip.